After more than three years of disagreement and stalemate, Vertex Pharmaceuticals Inc. and NHS England have agreed an access deal for the company’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor).
The row over Orkambi’s £100,000 per patient per year list price became one of the most high profile drug price...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
